Video Shorts
1:41
Examining the Implications of the VIKTORIA-1 Study 2 Data in PIK3CA-Mutated Breast Cancer
4 months ago
by
Sara A. Hurvitz, MD, FACP
1:37
Explaining the Prognostic Implications of Post-Surgical ctDNA Status in Early TNBC
4 months ago
by
Ruta D. Rao, MD
1:25
Exploring the Potential Role of AI-Augmented Surgery in CRC
4 months ago
by
James T. McCormick, DO
0:55
ASCO 2026 Conference Check-In: With Jonathan Lee, MD, MSc and Matthew Nguyen, MD
4 months ago
by
Jonathan Lee, MD, MSc
2:35
Assessing Luspatercept Data for Anemia in Myelofibrosis
4 months ago
by
Claire Harrison, MD
0:46
Highlighting the FDA Approval of Post-Neoadjuvant T-DXd for HER2+ Breast Cancer
4 months ago
by
Charles E. Geyer, MD
0:40
Spotlighting the BRIA-ABC Trial of Bria-IMT in Metastatic Breast Cancer
4 months ago
by
Saranya Chumsri, MD
0:43
Highlighting the DESTINY-Breast09 Trial of T-DXd Plus Pertuzumab in HER2+ Breast Cancer
4 months ago
by
Paolo Tarantino, MD
0:45
Integrating Adjuvant Belzutifan Plus Pembrolizumab into the ccRCC Treatment Paradigm
4 months ago
by
Toni Choueiri, MD
0:44
Examining the Potential Role of Aglatimagene Besadenovec in Prostate Cancer
4 months ago
by
Mark Garzotto, MD
0:52
Pathology or Pastry at WCCL 2026!
4 months ago
by
Amy Musiek, MD(+2 more)
0:28
Seeing if Experts Can Get on the Same Wavelength at WCCL 2026!
4 months ago
by
Jade Cury-Martins, MD, PhD(+1 more)
0:50
ASCO 2026 Conference Check-In: With Jonathan Lee, MD, MSc and Dr Manju George
4 months ago
by
Jonathan Lee, MD, MSc
1:06
Stopping Mogamulizumab Treatments in Patients with SS After Achieving CR
4 months ago
by
Marie Beylot-Barry, MD, PhD
0:37
Highlighting the Efficacy and Safety of Ipatasertib Plus Pembrolizumab in HNSCC
4 months ago
by
Jacob Stephen Thomas, MD
1:40
Examining the Potential Role of B7-H3 Inhibition in Prostate Cancer
4 months ago
by
Nicholas Zorko, MD, PhD
0:40
Highlighting the Safety Profile of Sacituzumab Govitecan/Pembrolizumab in TNBC
4 months ago
by
Sara M. Tolaney, MD, MPH
0:21
Comparing PSMA PET/CT vs 11C-Choline PET/CT for Disease Progression Monitoring in mCRPC
4 months ago
by
Eman E. Ahmed, MB, BCh
0:47
Diving into Key Multiple Myeloma Data From ASCO 2026
4 months ago
by
Noa Biran, MD
0:57
Highlighting the Role of MRD Testing in Breast Oncology
4 months ago
by
Priya Rastogi, MD
0:41
Exploring the Potential Role of Detalimogene Voraplasmid in NMIBC
4 months ago
by
Ashish M. Kamat, MD
1:05
The Potential of In Vivo CAR T-Cell Therapy in Multiple Myeloma
4 months ago
by
Andrew Spencer, MBBS, FRACP, FRCPA, DM
0:46
Spotlighting the Potential Benefits of the SERENA-6 Trial Design in Breast Cancer
4 months ago
by
Adam M. Brufsky, MD, PhD
1:40
Examining the Cognitive Effects of Darolutamide vs Enzalutamide in Prostate Cancer
4 months ago
by
Alicia Morgans, MD, MPH, FASCO
0:50
ASCO 2026 Conference Check-In: With Jonathan Lee, MD, MSc and Manish A. Shah, MD
4 months ago
by
Jonathan Lee, MD, MSc
0:57
The Significance of the phase 3 frontMIND Data in High-Risk DLBCL
5 months ago
by
Bhavana Bhatnagar, DO
0:50
ASCO 2026 Conference Check-In: With Jonathan Lee, MD, MSc and Sean Dougherty, MD
5 months ago
by
Jonathan Lee, MD, MSc
0:50
Evaluating the Effect of Response Depth on Treatment Outcomes in DESTINY-Breast09
5 months ago
by
Sara M. Tolaney, MD, MPH
0:49
Assessing Giredestrant-Based Therapy in ER+, HER2-Negative Advanced/Metastatic Breast Cancer
5 months ago
by
Mabel Mardones, MD
3:45
Exploring Notable Posters at the 2026 ASCO Annual Meeting
5 months ago
by
Chinmay Jani, MD
Advertisement
Advertisement
Trending on OncLive
1
Breast Cancer Experts Spotlight Practice-Informing and Thought-Provoking Data From ESMO 2026
2
TP53 Comutations, Long-Term Toxicity, and Sunvozertinib Access Shape EGFR+ NSCLC Treatment Decisions
3
Phase 1 Study of BGB-B2033 (GPC3 x 4-1BB Bispecific Antibody) Monotherapy: First Disclosure of Dose Optimization and Dose Escalation Update in Advanced Hepatocellular Carcinoma
4
Outpatient Models and Prophylactic Measures Help Bring Bispecifics Into Community Practice for R/R Myeloma
5